Characteristics of subjects
| . | Age, years . | Sex, F/M . | BMPR2 mutation, +/− . | Mean PAP, mm Hg . | Cardiac output, L/min . | PVR, wood unit . | RVSP, mm Hg . | ERA, +/− . | Prostacyclin, +/− . | Sildenafil, +/− . |
|---|---|---|---|---|---|---|---|---|---|---|
| IPAH | 43 ± 3 | 20/4 | 3/21 | 52 ± 3 | 5.5 ± 0.5 | 9.6 ± 1.8 | 70 ± 5 | 14/24 | 21/3 | 8/16 |
| FPAH | 41 ± 4 | 10/3 | 4/9 | 58 ± 7 | 3.4 ± 0.3 | 14.6 ± 3.0 | 66 ± 7 | 7/13 | 6/7 | 7/6 |
| APAH | 56 ± 3 | 11/4 | 0/11 | 50 ± 5 | 5.3 ± 0.6 | 8 ± 2 | 77 ± 8 | 9/15 | 7/15 | 7/8 |
| Controls | 35 ± 1 | 46/16 | ||||||||
| P | < .01 | .8 | .06 | .6 | < .01 | .1 | .6 | .6 | .2 | .4 |
| . | Age, years . | Sex, F/M . | BMPR2 mutation, +/− . | Mean PAP, mm Hg . | Cardiac output, L/min . | PVR, wood unit . | RVSP, mm Hg . | ERA, +/− . | Prostacyclin, +/− . | Sildenafil, +/− . |
|---|---|---|---|---|---|---|---|---|---|---|
| IPAH | 43 ± 3 | 20/4 | 3/21 | 52 ± 3 | 5.5 ± 0.5 | 9.6 ± 1.8 | 70 ± 5 | 14/24 | 21/3 | 8/16 |
| FPAH | 41 ± 4 | 10/3 | 4/9 | 58 ± 7 | 3.4 ± 0.3 | 14.6 ± 3.0 | 66 ± 7 | 7/13 | 6/7 | 7/6 |
| APAH | 56 ± 3 | 11/4 | 0/11 | 50 ± 5 | 5.3 ± 0.6 | 8 ± 2 | 77 ± 8 | 9/15 | 7/15 | 7/8 |
| Controls | 35 ± 1 | 46/16 | ||||||||
| P | < .01 | .8 | .06 | .6 | < .01 | .1 | .6 | .6 | .2 | .4 |
BMPR2 indicates bone morphogenetic protein receptor; F/M, female/male; PAP, pulmonary arterial pressure; PVR, pulmonary vascular resistance; RVSP, right ventricular systolic pressure; ERA, endothelin receptor antagonist; IPAH, idiopathic pulmonary arterial hypertension; FPAH, familial pulmonary arterial hypertension; and APAH, associated pulmonary arterial hypertension.